Oppilan Pharma is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative small molecule therapeutics for the management of autoimmune conditions. Our primary pharmaceutical candidate, OPL-002, is a powerful and specific regulator of sphingosine 1 phosphate receptor subtype 1 (S1P1) currently being developed for the treatment of inflammatory bowel disease. In December 2018, we commenced a Phase 1 clinical trial involving OPL-002.